Fig. 4.

WW437 significantly inhibited EphA2 involved signaling in breast cancer. A receptor tyrosine kinase (RTK) array kit was used to screen RTKs altered with WW437 treatment in MDA231 cell line. Cells were treated with 1 μM WW437 for 24 h, and lysates were hybridized to the array. (a) RTK array hybridization signals were shown. Black box showed RTKs significantly altered with WW437 treatment. (b) A Co-IP assay was performed to detect the p-Tyr of EphA2 and EphA2 expression. (c) EphA2 was immunoprecipiated and adjusted to equal in different groups. Western blot assays were performed using indicated antibodies. (d) MDA231 was treated with EphA2 siRNAs and EphA2 inhibitor (ALW-II-41-27). Western blot analysis was performed to detect the level of indicated proteins. (e) Western blot analysis was performed to detect the level of indicated proteins.